Arbeitsgruppe Hepatobiliäre Tumoren - Studien
| Frühes HCC, kurativ, Erstlinie |
||||
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0417/ass: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) (IMMULAB) | ||||
| --- in Vorbereitung, Studienstart noch offen, geplant Q4/2018 --- | ||||
| Hepatocellular Carcinoma, First Line | ||||
| AIO-assoziierte Studie | Weitere Zentren auf Anfrage |
www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0318/ass: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations | ||||
| --- in Rekrutierung--- | ||||
| HCC, periinterventionelle Studie, Erstlinie |
||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0217: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) (IMMUTACE) | ||||
| --- in Rekrutierung --- | ||||
| Fortgeschrittenes HCC, First line |
||||
| AIO-assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-HEP-0218/ass: An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) [IMMUNIB] | ||||
| --- in Vorbereitung, FPI Q4/2018 geplant --- | ||||
| Fortgeschrittenes intrahepatisches BTC, First line | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-HEP-0119/ass: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care [IMMUWHY] | ||||
| --- in Vorbereitung, FPI Q2/2019 geplant --- | ||||
| Cholangio- and Gallbladder Carcinoma, Erstlinie |
||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0117: A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma [IMMUCHEC] | ||||
| --- in Rekrutierung --- | ||||
| AIO-Studie | Weitere Zentren erwünscht |
www.clinicaltrials.gov | zur Studie | |
| AIO-YMO/HEP-0315: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial (NIFE) | ||||
| ---in Rekrutierung--- | ||||
| Cholangiozelluläres Karzinom, Zweitlinie | ||||
| AIO-Studie | Für weitere Zentren offen |
www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC) | ||||
| ---in Rekrutierung--- | ||||
| Cholangiokarzinom (intra- und extrahepatisch), Gallenblasenkarzinom, Zweitlinie | ||||
| AIO-Studie | zur Studie | |||
| AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL) | ||||
| ---in Vorbereitung --- | ||||
| Cholangiozelluläres Karzinom | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0112: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial | ||||
| ---in Rekrutierung--- | ||||
| Neoadjuvante Studie zum Cholangio- und Gallenblasen-Karzinom | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0118/ass: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR) – The AIO/ CALGP/ ACO- GAIN-Trial - |
||||
| ---in Vorbereitung, Studienstart noch in 2018 geplant, weitere Zentren sind sehr erwünscht! --- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 12.12.2018 |